The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-08 and is reviewed periodically as new material appears.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Redox ( RED-oks, REE-doks, reduction–oxidation or oxidation–reduction) is a type of chemical reaction in which the oxidation states of the reactants change. Oxidation is the loss of electrons or an increase in the oxidation state. Reduction is the gain of electrons or a decrease in the oxidation state. The oxidation and reduction processes occur simultaneously in the chemical reaction. Redox reactions fall into two classes. In electron transfer, a single electron usually flows from the atom, ion, or molecule being oxidized to the one being reduced; this is often described in terms of redox couples and electrode potentials. In atom transfer, an atom passes from one substrate to another; for example, in the rusting of iron the oxidation state of the iron atoms increases as the metal converts to an oxide and oxygen is reduced as it absorbs the released electrons. Redox reactions occur throughout nature and industry. Cellular respiration and photosynthesis, combustion, and the corrosion of metals all proceed through redox chemistry, as do the reactions that power batteries and other electrochemical cells. Industry uses redox reactions to extract metals from their ores by smelting, to electroplate objects, and to manufacture chemicals such as nitric acid. In soils, sediments, and water, redox gradients drive the biogeochemical cycling of elements.
"APS user shares the "Israeli Nobel" for chemistry", from the Argonne National Laboratory Advanced Photon Source (APS), United States Department of Energy The Official Site of Louisa Gross Horwitz Prize Weizmann Institute of Science, Yonath-Site Talk by Ada Yonath at the Origins 2011 congress Ada E. Yonath on Nobelprize.org Ada Yonath at IMDb
This detector works only for organic / hydrocarbon containing compounds due to the ability of the carbons to form cations and electrons upon pyrolysis which generates a current between the electrodes. The increase in current is translated and appears as a peak in a chromatogram. FIDs have low detection limits (a few picograms per second) but they are unable to generate ions from carbonyl containing carbons. FID compatible carrier gasses include helium, hydrogen, nitrogen, and argon. In FID, sometimes the stream is modified before entering the detector. A methanizer converts carbon monoxide and carbon dioxide into methane so that it can be detected. A different technology is the polyarc, by Activated Research Inc, that converts all compounds to methane. Alkali flame detector (AFD) or alkali flame ionization detector (AFID) has high sensitivity to nitrogen and phosphorus, similar to NPD. However, the alkaline metal ions are supplied with the hydrogen gas, rather than a bead above the flame. For this reason AFD does not suffer the "fatigue" of the NPD, but provides a constant sensitivity over long period of time. In addition, when alkali ions are not added to the flame, AFD operates like a standard FID. A catalytic combustion detector (CCD) measures combustible hydrocarbons and hydrogen. Discharge ionization detector (DID) uses a high-voltage electric discharge to produce ions. Flame photometric detector (FPD) uses a photomultiplier tube to detect spectral lines of the compounds as they are burned in a flame.
Sources: en.wikipedia.org
The aromatic acids 3-phenylpropionic acid (3PPA) and 3-(4-hydroxyphenyl)propionic acid (HPPA) are important commodities used in the chemical, pharmaceutical, and food industrial sectors. A biosynthetic route to synthetize these compounds was designed by combining the Escherichia coli phenylalanine pathway with non-native enzymes like tyrosine ammonia lyase (TAL) and the clostridial EnoR. The full pathway was assembled in Escherichia coli, which led to the production of HPPA and cinnamyl alcohol. Optimization of individual enzyme expression levels produced 3PPA and HPPA with a concentration of 367 and 225 mg/L, in this case the oxygen-sensitive EnoRs were catalytically active under the microaerophilic fermentation conditions. The 2-methylsuccinic acid (2-MSA) is used to synthetize polymers that have application as bioplastics, cosmetic solvents and coatings. A pathway for its synthesis was designed using Escherichia coli, combining native pyruvate and acetyl-CoA biosynthesis with methanogenic citramalate synthase (CimA), isopropylmalate isomerase (LeuCD), and the ER YqjM or KpnER from Klebsiella pneumoniae. The successful production of 2-MSA was achieved with a concentration of 0.96 g/L using KpnER.
=== Side reactions === The three main side reactions that produce impurities have in common that they decompose urea. Urea hydrolyzes back to ammonium carbamate in the hottest stages of the synthesis plant, especially in the stripper, so residence times in these stages are designed to be short. Biuret is formed when two molecules of urea combine with the loss of a molecule of ammonia.
But in the Psychedelics Encyclopedia, author Peter Stafford writes: "The psilocybin experience seems to be warmer, not as forceful and less isolating. It tends to build connections between people, who are generally much more in communication than when they use LSD."
== Jeewanu protocell == A further protocell model is the Jeewanu. First synthesized in 1963 from simple minerals and basic organics while exposed to sunlight, it is reported to have some metabolic capabilities, the presence of a semipermeable membrane, amino acids, phospholipids, carbohydrates and RNA-like molecules. However, the nature and properties of the Jeewanu remains to be clarified. Electrostatic interactions induced by short, positively charged, hydrophobic peptides containing 7 amino acids in length or fewer can attach RNA to a vesicle membrane, the basic cell membrane.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.